Windtree Therapeutics is advancing multiple late-stage interventions for acute cardiovascular and pulmonary syndromes to support patients in their moments of crisis. Windtree's goal is to develop unique therapies that significantly improve upon the treatment of severe, acute conditions, such as heart failure, early cardiogenic shock, lung injury associated with COVID-19 and neonatal respiratory distress--addressing some of the most underserved and costly acute conditions.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):